A clinical trial is a study conducted with actual patients, usually to evaluate a new treatment. Each study is designed to answer scientific questions and to find new and better ways to help patients.
Technical Title: A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab Combination vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse
Disease Type: Patients with renal cell carcinoma (a type of kidney cancer) who are planned to have a nephrectomy (surgical removal of the kidney)
Basic information: The purpose of this study is to compare the effectiveness, safety, and tolerability of an investigational drug combination in patients with localized kidney cancer that have had their tumors completely removed, but are at risk of having their cancer return. The drug combination includes two drugs: nivolumab (also known as OPDIVO) and ipilimumab (also known as Yervoy).
For More Detailed Information, Contact:
• Brian Shuch, MD, Principal Investigator
• Sara Rodriguez, Study Coordinator, (310) 794-2877
Read more about this study (NCT03138512) on ClinicalTrials.gov.
Technical Title: 99mTc-sestamibi Imaging for the Characterization of Renal Masses:
Impact on Clinical Decision Making
Disease Type: Patients with recently diagnosed renal masses
Basic information: The purpose of this study is to examine how doctors and patients use information from 99mTc-sestamibi SPECT/CT, a type of nuclear medicine scan, to decide how to manage newly diagnosed renal masses (kidney tumors). Patients on this study will undergo 99mTc-sestamibi SPECT/CT scans as part of their routine care.
For More Detailed Information, Contact:
• Brian Shuch, MD, Principal Investigator
• Sara Rodriguez, Study Coordinator, (310) 794-2877
Technical Title: PROSPER RCC: EA8143: A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy
Disease Type: Patients with renal cell carcinoma (a type of kidney cancer) who are planned to have a nephrectomy (surgical removal of the kidney)
Basic information: The purpose of this study is to compare the effects of a drug called nivolumab (also known as OPDIVO®), before and after the kidney cancer surgery to using the usual approach of surgically removing the kidney cancer followed by standard post-operative follow-up and monitoring. Nivolumab is a drug that may help stimulate your immune system to attack any cancer cells that may remain after surgery. The addition of nivolumab to the usual surgery could prevent your cancer from returning but it could also cause side effects.
For More Detailed Information, Contact:
• Brian Shuch, MD, Principal Investigator
• Rosleen Mala, Study Coordinator, (310) 794-3879
For information on inclusion and exclusion criteria please call our Clinical Trials Office - 310-206-5930
